Welcome to our dedicated page for Cavitation Technologies SEC filings (Ticker: CVAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cavitation Technologies, Inc. (OTCQB: CVAT) filings page on Stock Titan is designed to help readers review the company’s regulatory disclosures alongside AI-generated context. While no specific SEC filings are listed in the provided data, investors typically look to documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K to understand how a company describes its business, risks, and material events.
For a company like Cavitation Technologies, Inc., which reports that it designs and manufactures patented nano-technology systems for fluid processing and water treatment, SEC filings can offer detail on its Nano Reactor® and Cavitation Non-Thermal Plasma™ (CNTP) technologies, intellectual property portfolio, and the range of industries it serves, including water remediation, agriculture, pharmaceuticals, oil & gas, edible oil refining, renewable fuels, beverages, PFAS removal, and digital asset infrastructure.
Filings can also provide information about licensing arrangements and subsidiaries, such as the exclusive CNTP license granted to XYRA Corp. for submerged fluid cooling in cryptocurrency mining and data center immersion cooling, and XYRA’s activities in AI-driven, quantum-secure remittance and fintech infrastructure. When available, Forms 4 and related ownership reports may shed light on insider transactions, while proxy statements can discuss governance and compensation structures.
On Stock Titan, AI tools summarize lengthy filings, highlight key sections, and surface items that may be relevant to CVAT’s technology focus and strategic direction. As new SEC documents are filed to EDGAR, they can be incorporated into this page, giving users a single location to review Cavitation Technologies, Inc.’s regulatory history with added explanatory context.
Cavitation Technologies, Inc. reported a sharp downturn for the quarter ended December 31, 2025. Revenue fell to $0 from $76,000 a year earlier as prior-period Nano Reactor® sales tied to patents sold to Desmet did not repeat. Operating expenses rose to $474,000, driven mainly by higher stock-based compensation, leading to an operating loss of $474,000.
There was no repeat of the prior-year $880,000 gain on patent assignment, so the company swung from net income of $579,000 to a net loss of $476,000 for the quarter, and a $734,000 loss for the six months. Cash declined to $31,000, total assets were $55,000, and stockholders’ deficit was $248,000, while liabilities totaled $303,000.
The 10-Q highlights substantial doubt about the company’s ability to continue as a going concern, citing continuing operating losses, limited cash, and reliance on raising additional capital and executing new revenue initiatives in water treatment, agriculture, beverage technology, hydro-plasma, and its new Xyra crypto-related subsidiary. As of February 13, 2026, 309,720,740 common shares were outstanding.
Cavitation Technologies (CVAT)$3,000 from a short‑term equipment rental. Operating expenses were $252,000, driving a loss from operations of $249,000. Interest expense rose to $9,000 after reconciling its SBA EIDL loan, resulting in a net loss of $258,000.
Cash used in operations was $219,000, leaving $30,000 in cash at quarter‑end. Total assets were $60,000 against total liabilities of $249,000, producing a stockholders’ deficit of $(189,000). The company had 289,156,340 common shares outstanding as of
Cavitation Technologies, Inc. (CVAT) reported fiscal year results showing limited revenue and material operating losses. Revenue for the period was $165,000 while cost of revenue was $1,207,000, producing a gross loss of $1,042,000. Total operating expenses were $1,152,000, including $1,057,000 of general and administrative expenses, resulting in a loss from operations of $987,000. The company recorded an $880,000 gain on patent assignment which was collected in full. As of June 30, 2025 the company had an accumulated deficit of $26,960,000 and management disclosed substantial doubt about the company’s ability to continue as a going concern, while stating available cash to sustain operations through December 2025. Significant concentration: 98% of revenue derived from Desmet Belgium. Shares outstanding totaled 289,156,340.